High-level expression, purification, and enzymatic characterization of truncated human plasminogen (Lys531-Asn791) in the methylotrophic yeast Pichia pastoris by Rongzeng Liu et al.
Liu et al. BMC Biotechnology  (2015) 15:50 
DOI 10.1186/s12896-015-0179-zRESEARCH ARTICLE Open AccessHigh-level expression, purification, and
enzymatic characterization of truncated
human plasminogen (Lys531-Asn791) in
the methylotrophic yeast Pichia pastoris
Rongzeng Liu1,2, Bing Zhao1,2, Yanling Zhang1,2, Junxiang Gu1,2, Mingrong Yu1,2, Houyan Song1,2,3, Min Yu1,2
and Wei Mo1,2*Abstract
Background: Plasmin is a serine protease that plays a critical role in fibrinolysis, which is a process that prevents
blood clots from growing and becoming problematic. Recombinant human microplasminogen (rhμPlg) is a
derivative of plasmin that solely consists of the catalytic domain of human plasmin and lacks the five kringle
domains found in the native protein. Developing an industrial production method that provides high yields of this
protein with high purity, quality, and potency is critical for preclinical research.
Results: The human microplasminogen gene was cloned into the pPIC9K vector, and the recombinant plasmid was
transformed into Pichia pastoris strain GS115. The concentration of plasmin reached 510.1 mg/L of culture medium.
Under fermentation conditions, the yield of rhμPlg was 1.0 g/L. We purified rhμPlg to 96 % purity by gel-filtration
and cation-exchange chromatography. The specific activity of rhμPlg reached 23.6 U/mg. The Km of substrate
hydrolysis by recombinant human microplasmin was comparable to that of human plasmin, while rhμPlm had
higher kcat/Km values than plasmin. The high purity and activity of the rhμPlg obtained here will likely prove to
be a valuable tool for studies of its application in thrombotic diseases and vitreoretinopathies.
Conclusions: Reliable rhμPlg production (for use in therapeutic applications) is feasible using genetically
modified P. pastoris as a host strain. The successful expression of rhμPlg in P. pastoris lays a solid foundation for
its downstream application.
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Plasminogen, the proenzyme precursor of the primary
fibrinolytic protease, plasmin, is a single-chain protein
containing of 791 amino acid residues [1]. While plas-
minogen is expressed in all major organs and tissues, it
is synthesized primarily in the liver [2]. Plasminogen is
found in significant quantities in extravascular fluids
[3]. Circulating plasminogen comprises a Pan-apple
(PAp) domain, five kringle domains (KR1–5), and a* Correspondence: weimo1025@shmu.edu.cn
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(http://creativecommons.org/publicdomain/zeroserine protease (SP) domain [4]. Under physiological con-
ditions, plasminogen is converted to plasmin by a cleavage
event that occurs in its activation loop (between Arg561
and Val562), which is facilitated by tissue plasminogen
activator (tPA) or urokinase plasminogen activator
(uPA). The plasmin molecule is a two-chain, disulfide-
linked SP with trypsin-like specificity. The C-terminal
light chain of plasmin (residues 562–791, molecular
weight (MW) 25 kDa) contains a typical SP that is
homologous to trypsin. The C-terminal light chain also
contains the classic catalytic triad, which is composed
of His603, Asp646, and Ser741.
Plasmin can undergo an autolytic process, and its
cleavage site specificity can change with pH. The specificle distributed under the terms of the Creative Commons Attribution
es/by/4.0), which permits unrestricted use, distribution, and reproduction in
properly credited. The Creative Commons Public Domain Dedication waiver
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lutions leads to the formation of a low-molecular-weight
form of plasmin, termed microplasmin [5]. Human
microplasmin (Lys531–Asn791), which was first pre-
pared from plasmin in an alkaline solution, consists of
two polypeptide chains that are connected by disulfide
bonds. One polypeptide is the B chain of plasmin that
consists of 230 amino acids, while the other peptide is
the C-terminal portion of the A chain of plasmin, which
consists of 31 amino acid residues [6]. Microplasmin has
a molecular weight of 28 kDa, as calculated from its pri-
mary sequence. It is slightly more positively charged
than plasminogen, and it is generally a more hydropho-
bic molecule [6].
The dissolution of blood clots, whether accomplished
physiologically or pharmacologically, is facilitated by
plasmin [7]. Plasmin was first studied more than 50 years
ago, and it was found to be either ineffective or inferior
to plasminogen activators in treating thrombotic diseases
[8]. With the current widespread use of catheters to de-
liver thrombolytic therapy, plasmin has been reevaluated
as a potentially valuable thrombolytic agent; pharmaco-
logical studies have demonstrated plasmin is an effective
and hemostatically-safe application for the treatment of
thrombotic diseases [9]. In addition to fibrin, plasmin
has been shown to directly degrade other extracellular
matrix (ECM) components, including laminin and fi-
bronectin, which have a postulated role in vitreoretinal
adhesion [10, 11]. In both enucleated pig and human
eyes, the addition of 1 U of plasmin eliminates the cortical
vitreous remnants previously detected on the inner
limiting membrane, all without the use of adjunctive
techniques [12, 13].
However, the isolation of autologous plasmin is a
costly and time-consuming process. Furthermore, it is
difficult to produce plasmin via recombinant gene tech-
nology because of its high molecular weight and ten-
dency to degrade [14]. Therefore, the availability of
lower molecular weight and more stable microplasmino-
gen (μPlg) represents a valuable tool that might be ap-
plied to the treatment of thrombotic diseases and
vitreoretinopathies (pending preclinical and clinical
evaluation). In response to this need, we developed a
protocol to produce abundant quantities of highly active
and high-purity rhμPlg (Lys531–Asn791) from Pichia
pastoris.
Results
Construction of plasmid pPIC9K-hμPlg
A full-length DNA sequence of the synthetic hμPlg gene
was inserted into the open reading frame of the α-factor
signal sequence of the P. pastoris expression vector
pPIC9K, which is under the regulation of the AOX1 pro-
moter (Additional file 1). This plasmid was transformedinto Escherichia coli DH5α to express hμPlg. Enzyme di-
gestion demonstrated that the hμPlg gene was correctly
oriented in the pPIC9K vector (Additional file 1). DNA
sequencing of the recombinant vector confirmed the ac-
curacy of the reading frame of hμPlg, and P. pastoris
GS115 positive transformants were successfully identi-
fied. The plasmid pPIC9K-hμPlg contained a 783-bp
inserted target fragment. The deduced mature cDNA se-
quence of rhμPlg encodes a 261-amion acid peptide with
a theoretical MW of 28.63 kDa and a pI of 7.95.
Transformation and screening of transformants
After linearization with SalI, pPIC9K-hμPlg was trans-
formed into P. pastoris GS115 competent cells by electro-
poration. After an initial selection of His + transformants,
clones were grown in microtiter plates until they reached
the same optical density. The cultures were then spotted
onto yeast extract-peptone-dextrose (YPD)-Geneticin
plates (containing 2.0 mg/mL of Geneticin) and scored for
Geneticin resistance. Five transformants, B2, B6, C3, F2,
and F6, were obtained on the YPD-Geneticin plates. After
genomic DNA was isolated from P. pastoris recombinants
and controls, polymerase chain reaction (PCR) verification
of the positive recombinants was performed using 5′ and
3′ AOX1 sequencing primers. Two bands were obtained
for pPIC9K-hμPlg: one corresponding to the size of
the hμPlg gene plus the inserted AOX1 gene in pPIC9K
(783 + 492 bp), and the other corresponding to the AOX1
gene in the chromosome of P. pastoris.
Expression of rhμPlg in a shaker flask and a 5-L
bioreactor
The selected transformants (B2, B6, C3, F2, and F6) were
cultured in a shaker flask to measure rhμPlg expression.
Maximum expression was observed after 4 days of
methanol induction at 30 °C. Supernatant proteins were
subjected to sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) analysis (Fig. 1, lanes 1–5).
As shown in Fig. 1, a predominant band at approxi-
mately 35 kDa was observed in lanes 1–5. No target
band was detected in the cultures of an induced trans-
formant harboring an empty pPIC9K plasmid. GS115 F2
showed a distinctive band (lane 5), with a yield that
reached 510.1 mg/L after 96 h of induction. Therefore,
GS115 F2 was used for the subsequent expression of
rhμPlg.
As shown in Fig. 2a, fermentation was conducted in a
5-L bioreactor. The culture medium was collected and
centrifuged every 5 h to obtain supernatants. Recombin-
ant protein expression started 5 h after methanol induc-
tion and reached a peak at 40 h (Fig. 2a). At the end of
the glycerol fed-batch phase, the biomass concentration
reached 90 g/L. The methanol fed-batch phase of rhμPlg
production lasted for 40 h, and the final biomass
Fig. 1 Production of rhμPlg in P. pastoris GS115 using a shaker flask.
This figures shows the SDS-PAGE analysis of rhμPlg in fermentation
supernatants from different transformants induced for 96 h in shaker
flask cultures. Lanes 1–5A are loaded with 20 μl of fermentation
supernatants from different transformants; lane M contains 10 μl
of molecular mass standards
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supernatant increased to 3.4 L. After 40 h of induction,
the total secreted protein concentration was 1.88 g/L,
and the rhμPlg activity in the supernatant reached 7.9
U/mL, which was 15 times that of the shaker flask
fermentation.
Purification of rhμPlg
The concentration of rhμPlg in the bioreactor culture
supernatant was estimated to be 1.0 g/L based on SDS-
PAGE. The rhμPlg expressed by P. pastoris was purified to
homogeneity by ultrafiltration, followed by cation-exchange
and Superdex 75 gel-filtration chromatography. The cultureFig. 2 Expression and purification of rhμPlg. a, SDS-PAGE analysis of rhμPlg
(14.4–116.0 kDa); Lane 1, uninduced P. pastoris; Lanes 2–9, P. pastoris induc
protein marker. Lane 1, gel-filtration chromatography wash fraction; Lane 2
blot of rhμPlgsupernatant was collected and concentrated using mem-
brane ultrafiltration. Subsequently, concentrated super-
natant was loaded onto an SP Sepharose Fast Flow column,
which bound most of the rhμPlg (Fig. 2b). rhμPlg was
eluted at 0.35 mol/L in NaCl-acetate buffer. rhμPlg was fur-
ther purified via high-resolution gel-filtration chromatog-
raphy to remove trace impurities. Finally, we obtained
167 mg of purified rhμPlg per liter of culture supernatant
(Additional file 2). The specific activity of purified rhμPlg
reached 23.6 U/mg protein (Additional file 2). The eluates
containing rhμPlg were analyzed using SDS-PAGE,
followed by western blotting using a polyclonal antibody.
The purity of rhμPlg reached 96 %, as determined by
SDS-PAGE (Fig. 2b, lane 2).
Characterization of rhμPlg
N-terminal sequencing indicated that the 10 amino acid
residues at the N-terminus of rhμPlg were KLY-
DYCDVPQ, which matched the deduced amino acid se-
quence of mature hμPlg. We determined that the secreted
active protein contained 261 amino acids, which is consist-
ent with the size of full-length hμPlg.
Mass spectrometry analysis
An accurate mass can be detected by intact mass ana-
lysis using liquid chromatography-mass spectrometry
(LC-MS). Peaks corresponding to various protonated
rhμPlg species were determined. The mass analysis de-
termined that rhμPlg has a molecular weight of
28.55 kDa (Fig. 3). This is identical to that identified by
SDS-PAGE.
Amidolytic assays and kinetic analysis
Both plasmin and rhμPlg possess amidolytic activity
against chromogenic substrates. The kinetic parameters
Km, kcat, and kcat/Km for such substrates are summarizedexpressed by fed-batch fermentation. Lane 1, standard protein marker
ed with methanol for 5, 10, 15, 20, 25, 30, 35, and 40 h. b, M, standard
, cation-exchange chromatography wash fraction 3; Lane 3, western
Fig. 3 Molecular mass determination of purified rhμPlg by LC-MS. Peaks corresponding to various protonated rhμPlg species are marked.
The mass analysis determined that rhμPlg has a molecular weight of 28.55 kDa
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comparable to that by human plasmin (Table 1), suggest-
ing that kringle domains 1–5 had no effect on the cata-
lytic activity of plasmin. We also found that rhμPlg had
higher kcat/Km values than plasmin. The difference in
the kcat/Km values of the two proteinases was caused
mainly by a variance in kcat (Table 1), which implied that
there was a structural difference between the two pro-
teins, probably owing to the closed conformation of
plasmin. In addition, both serine proteases hydrolyzed a
fibrin plate in a concentration-dependent manner, with
slightly higher area values for rhμPlg (Fig. 4).
Discussion
Plasminogen and its active form (plasmin) play import-
ant physiological and pathological roles in fibrinolysis





Km (mM) kcat (S
−1)* kcat/Km (mM
−1 · S−1)*
Plasminogen 0.325 ± 0.016 30.6 ± 2.5 94.15 ± 0.03
rhμPlg 0.348 ± 0.021 44.5 ± 3.6 127.87 ± 0.01
Values given are means ± SEM (n = 3); *P values < 0.05migration, tissue remodeling, wound healing, angiogen-
esis, inflammation, and tumor cell migration [15]. Con-
sequently, patients with severe plasminogen deficiency
typically suffer from a range of difficult to treat inflam-
matory conditions, including ligneous conjunctivitis, gin-
givitis, and neural disorders [16, 17]. Activation of the
plasminogen system is tightly regulated, which is neces-
sary to prevent the development of a systemic fibrino-
lytic state or tumor metastasis. The availability of rhμPlg
with full enzymatic activity could be extremely valuable
for structure-function studies of plasminogen and plas-
min. In addition, its truncated derivative is also needed
for various important therapeutic applications, including
catheter-directed thrombolysis and treatment of acute
ischemic stroke [18], acute lower extremity arterial or
bypass graft occlusion [19], acute iliofemoral deep ven-
ous thrombosis [20] enzyme-induced vitreolysis, alleviat-
ing the progression of diabetic retinopathy [21], and
treatment of diabetic retinopathy in young adults [22].
rhμPlg has been expressed at high levels as inclusion
bodies in E. coli [23, 24]. Recently, the methylotrophic
yeast P. pastoris has been considered to be an excellent
host for producing proteins obtained from different
sources [25]. As a eukaryote, P. pastoris has many ad-
vantages. Proteins produced by P. pastoris are more
likely to be processed, properly folded, and chemically
Fig. 4 Fibrinolytic activity of rhμPlg and plasminogen in a plasminogen-free fibrin agar plate. a, 1–5, plasmin with a concentration of 5, 4, 3, 2,
and 1 U/mL, respectively; 6–10, rhμPlg with a concentration of 5, 4, 3, 2 and 1 U/mL, respectively; 11, PBS as negative control. b, Comparison of
the fibrinolytic activity of plasmin and rhμPlg as calculated from the area of the lysis zone
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culture, easier upscaling, and strong and tightly regu-
lated promoters have all been identified as advantages of
using P. pastoris as a host [26]. In this study, rhμPlg was
expressed in P. pastoris, which was achieved by express-
ing rhμPlg (comprising amino acids Lys531–Asn791),
which lacks the five kringle domains. This method pro-
duced high yields (1.88 g/L of fermentation broth) of
protein, which could be purified to homogeneity. The
MW of rhμPlg was different from that of the microplas-
mins produced by Nagai et al. and Joshi et al. [27, 28],
both of which lacked 12 N-terminal amino acids.
In this study, we cloned the cDNA gene of hμPlg into
a pPIC9K vector that contained an α-factor secretion
signal and allowed for the expression of hμPlg in P. pas-
toris GS115. Transformants were selected based on their
ability to grow on a medium lacking histidine, as well as
on their Geneticin resistance. Enzymatically active
rhμPlg, which had a MW of 28.55 kDa, was expressed.
Then, we developed a preparation of rhμPlg that was
suitable for pharmaceutical use. The final, optimized
process consists of a sequence of three chromatography
steps. The first step (gel filtration) desalts and exchanges
the buffer to acetate buffer, while the second step (cation
exchange) captures rhμPlg and allows contaminants to
flow through. A gel filtration/diafiltration step then
serves to transfer the recombinant protein into its for-
mulation buffer (20.0 mM phosphate buffer, pH 7.0).
The final concentration was 1 mg/ml in phosphate-
buffered saline (pH 7.0). A preliminary characterization
of rhμPlg was performed using western blotting, high-
performance liquid chromatography, mass spectrometry,
and N-terminal sequencing to verify the identity of the
protein. We also completed a partial characterization of
the functional properties of rhμPlg by comparing its
serine protease activity to that of commercially available
plasmin. Our assays showed that when using an amido-
lytic chromophogenic substrate, the Km value of rhμPlg
was similar to that of plasmin (Fig. 4). The catalytic effi-
ciency, kcat/Km, was higher for rhμPlg than plasmin.rhμPlg, at a concentration similar to that of plasmin,
exhibited a higher area value in the fibrinolysis plate,
suggesting that kringle domains 1–5 have no effect on
the catalytic activity of plasmin.
The development of rhμPlg may solve most of the
problems associated with the treatment of vitreoretino-
pathies with autologous plasmin. rhμPlg contains only
the enzymatic portion of the plasmin molecule, while
the other domains are omitted. This makes rhμPlg much
smaller than the original molecule (28 vs. 80 kDa, re-
spectively) while retaining the same enzymatic activity,
which theoretically would allow for greater penetration
into epiretinal tissues. rhμPlg has other advantages over
plasmin. First, it is commercially available, allowing in-
vestigators to avoid the time-consuming and expensive
steps necessary for the production of autologous plasmin
enzyme. Second, it is generated by recombinant tech-
niques, ensuring its sterility while avoiding the risk of
microbial contamination. Last, it is inherently more
stable than plasmin and can be stored in citrate buffer
prior to use [29].
Conclusions
Our results demonstrate that high-purity rhμPlg (Lys531–
Asn791) can be abundantly produced by P. pastoris.
After purification and identification of rhμPlg, we ob-
served fibrinolytic activity in vitro, which suggested
that rhμPlg might play an active and beneficial role in
treating thrombotic diseases and controlling the pro-
gression of vitreoretinopathies. Therefore, the possibility
of producing rhμPlg for use in therapeutic applications
could be fulfilled by P. pastoris. The successful expression
of rhμPlg in P. pastoris lays a solid foundation for its
possible future applications.
Methods
Strains, vectors, reagents, and enzymes
The multi-copy Pichia expression kit containing P. pas-
toris strain GS115 and the pPIC9K vector were pur-
chased from Invitrogen Corp. (Carlsbad, CA, USA). The
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Millipore, Billerica, MA, USA). E. coli cells containing
plasmids were cultured aerobically at 37 °C in Luria–
Bertani medium (5 g/L yeast extract, 10 g/L tryptone,
10 g/L NaCl, and 15 g/L agar) containing 100 μg/ml
ampicillin to maintain the plasmids. Minimal dextrose
(MD) medium, buffered complex glycerol medium
(BMGY), YPD medium, buffered complex methanol
medium (BMMY), and fermentation basal salts medium
(BSM) supplemented with PTM1 solution (0.2 g/L H3BO3,
6.0 g/L CuSO4
. 5H2O, 0.8 g/L KI, 3.0 g/L MnSO4
. 2H2O,
65 g/L FeSO4
. 7H2O, 0.2 g/L Na2MoO4
. 2H2O, 0.5 g/L
CoCl2, 20.0 g/L ZnCl2, 5 mL/L H2SO4, 0.5 g/L
CaSO4
. H2O, and 0.2 g/L biotin) were prepared according
to Invitrogen’s instructions for P. pastoris fermentation.
Restriction enzymes and kits for cloning were obtained
from New England Biolabs (Ipswich, MA, USA). The gene
of interest, obtained from NCBI (GenBank: M74220.1, hu-
man plasminogen mRNA, complete coding sequence, nu-
cleotides 1648–2430) was synthesized and cloned into
plasmid pUC57 by Sangon Biological Co., Ltd. (Shanghai,
China) (Additional file 3). The chromogenic substrate H-
D-Val-Phe-Lys-p-NA · 2HBr (S2390) was synthesized by
the School of Pharmacy, Fudan University [30].
Synthesis of the human μPlg gene and construction of
the expression vector
A DNA fragment was amplified by PCR using the syn-
thetic gene as a template, which yielded an 814-bp prod-
uct. The forward primer was 5′-CCGCTCGAGAAAAG
AAAACTTTACGACTACTGTG (the underlined se-
quence is an XhoI site), and the reverse primer was 5′-AT
AAGAATGCGGCCGCTTAATTATTTCTCATCACTCC
(the underlined sequence is a NotI site). The total reaction
volume was 20 μL, including 4 μL of 5× Phusion HF DNA
polymerase, 0.4 μL of 10 mM dNTPs, 1.0 μL of the for-
ward primer (10 mM), 1.0 μL of the reverse primer
(10 mM), 0.25 μL of Phusion DNA polymerase, 12.35 μL
of sterile water, and 1 μL of pUC57-μPlg (10 ng/μL). Amp-
lification conditions were 30 s at 98 °C, 30 cycles of 10 s
at 98 °C, 20 s at 49 °C, and 30 s at 72 °C, followed by a
final extension of 5 min at 72 °C. The PCR product was
ligated into the pPIC9K vector between the XhoI and
NotI sites. The recombinant plasmid was transformed
into E. coli JM109, and transformants were identified
by restriction digest analysis and sequencing. The the-
oretical MW and pI were calculated using the website
http://web.expasy.org/compute_pi/.
Transformation and screening of multi-copy
transformants
SalI was used to linearize 10 μg of the pPIC9K-hμPlg
plasmid, and the linear DNA was then transformed
into P. pastoris GS115 cells using a GenePulser system(Bio-Rad, Carlsbad, CA, USA) under the following con-
ditions: 1.5 kV, 200 Ω, and 25 μF). His + transformants
were selected on YPD plates containing Geneticin 418
(2–6 mg/ml), and then lysed by a combined enzyme, freez-
ing, and heating treatment according to a simple protocol
reported in the literature [31]. The cell lysate containing
the genomic DNA was analyzed by PCR using the
5′ AOX1 primer 5′-GACTGGTTCCAATTGACAAGC-3′
and the 3′ AOX1 primer 5′-GCAAATGGCATTCTGACA
TCC-3′. The total reaction volume was 50 μL, including
5 μL of 10× reaction buffer, 5 μL of 25 mM MgCl2, 1 μL of
25 mM dNTPs, 1 μL of the 5′ AOX1 primer (10 pmol/μL),
1 μL of the 3′ AOX1 primer (10 pmol/μL), 27 μL of sterile
water, and 5 μL of cell lysate. The reaction was incubated in
a thermocycler at 95 °C for 5 min, and 5 μl of a 0.16 U/μl
solution of Taq polymerase (0.8 units) was added. The
amplification conditions were 30 cycles of 1 min at 95 °C,
1 min at 54 °C and 1 min at 72 °C, followed by a final
extension of 7 min at 72 °C.
Production of rhμPlg in a shaking flask and a 5-L bioreactor
The colonies of His + transformants exhibiting resistance
to 2.0 mg/ml Geneticin were inoculated in 10 ml of
BMGY (2 % peptone, 1 % yeast extract, 100 mM potas-
sium phosphate, pH 6.0, 1.34 % yeast nitrogen base
(without amino acids), 0.4 μg/ml biotin, and 1 % gly-
cerol) at 30 °C with constant shaking at 250 rpm until
the OD600 was 4. To accurately measure OD600 > 1.0, a
sample of the culture was diluted 10-fold before reading.
The cells were then resuspended in 10 ml of BMMY
(2 % peptone, 1 % yeast extract, 100 mM potassium
phosphate, pH 6.0, 1.34 % yeast nitrogen base (without
amino acids), 0.4 μg/ml biotin, and 0.5 % methanol), and
expression was induced at 30 °C with constant shaking
at 250 rpm for 96 h. Methanol was added at a concen-
tration of 1 % (v/v) every 24 h. The supernatant was
collected for activity assays and SDS-PAGE analysis.
The inoculum seeds of P. pastoris were cultured at
30 °C on a shaker at 250 rpm for 24 h in 200 ml of YPD
medium. A total of 200 ml of the seed broth was inocu-
lated into a 5-L fermenter (Bioflo 3000 fermenter, New
Brunswick Scientific, New Brunswick, NJ, USA) contain-
ing 3 L of BSM plus 2 ml/L of PTM1 solution. The pH
of the medium was adjusted to and maintained at 5.0 via
the addition of ammonium hydroxide. The temperature
was maintained at 30 °C, and the dissolved oxygen level
was maintained at over 35 % of air saturation by a cas-
caded control of agitation speed and aeration rate. After
glycerol exhaustion, 200 ml of feeding medium contain-
ing 50 % (w/v) glycerol and 2 ml/L of PTM1 solution
were pumped into the bioreactor according to Invitro-
gen’s instructions for P. pastoris fermentation. After the
depletion of glycerol, pure methanol containing 2 ml/L
of PTM1 was added to the bioreactor. The production
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methanol feeding rate from 0.8 to 4 ml/L.h, which
allowed the culture to adapt to the methanol. After 6 h,
the methanol feed rate was maintained at 4 ml/L/h for
an additional 34 h. Samples were collected for the de-
termination of the OD600, dry cell weight, fibrinolytic
activity, and protein concentration.
Purification of rhμPlg
The culture was centrifuged and the supernatant was
ultrafiltered, followed by gel-filtration and cation-
exchange chromatography. The concentrated super-
natant was loaded onto a Sephadex G-50 column
(7.5 cm × 100 cm) that was already equilibrated with
20 mmol/L acetate buffer (pH 5.0). One thousand mil-
liliters of collected sample, which was eluted from the
gel-filtration column, was loaded onto a SP-Sepharose
FF column (2.6 cm × 20 cm), which was also equili-
brated with 20 mmol/L acetate buffer (pH 5.0). It was
washed with 20 mmol/L acetate buffer (pH 5.0),
followed by a single linear gradient of 0–1.0 mol/L
NaCl-acetate buffer. The fractions were collected for
activity assays and SDS-PAGE analysis, then desalted
with a Superdex 75 column (5.0 cm × 100 cm). Forty
milliliters of sample was loaded each time. The
desalted sample was lyophilized and stored at −80 °C.
Western blotting
Proteins resolved by SDS-PAGE were electrotransferred
to a polyvinylidene fluoride membrane followed by
blocking in 5 % skim milk prepared in Tris-buffered sa-
line containing 0.05 % Tween-20 (TBST). The membrane
was then incubated with an anti-rhμPlg polyclonal anti-
body (1:1000 dilution) (16776-1-AP, Proteintech Group,
Chicago, IL, USA) for 90 min at room temperature. After
washing, the membrane was incubated with a horseradish
peroxidase-conjugated goat anti-rabbit IgG (1:10,000
dilution) (CW0103, Cwbiotech, Beijing, China) for 60 min
at room temperature. All antibody incubations and
washing steps were conducted in TBST. Immunoreactive
bands were visualized with an enhanced chemilumines-
cent substrate (PA109, Tiangen Biotech, Beijing, China).
Mass spectrometry analysis
The purified protein was analyzed by mass spectrometry.
Molecular weight measurements were made by matrix-
assisted laser desorption-ionization time of flight mass
spectrometry (AB SCIEX) at the Shanghai Applied Protein
Technology Co., Ltd.
Amidolytic assays and kinetic analysis
Amidolytic activity was measured using H-D-Val-Phe-Lys-
p-NA · 2HBr, a chromogenic substrate containing a ρ-
nitroanilide (ρ-NA) group [32]. Human plasminogen wasused as a standard to calculate the activity units of rhμPlg.
Fifty microliters of substrate (1.25 mM) was added to 50-μl
solutions of various concentrations of proteinases in
50 mM Tris–HCl, pH 7.4. The release of ρ-NA was then
monitored continuously at 405 nm. The amount of sub-
strate hydrolyzed was calculated from the increase in ab-
sorbance at 405 nm, using a molar extinction coefficient of
10,000 M−1 · cm−1 for free ρ-NA. One unit of enzyme will
produce one umole of ρ-nitroanilide from H-D-Val-Phe-
Lys-p-NA · 2HBr per minute at 37 °C, pH 7.4 (Amidase
unit). The Michaelis constant (Km) and catalytic rate con-
stant (kcat) were determined from Lineweaver–Burk plots.
Enzyme assays and protein analysis
The catalytic activity of rhμPlg was assayed and compared
with that of plasminogen. Fibrinolysis was performed on a
fibrin plate, as described by Choi and Sa [33]. Briefly, a
mixture of 0.6 % (w/v) fibrinogen and 2 % (w/v) agar was
prepared in 50 mM sodium phosphate buffer at pH 7.4,
boiled for 2 min, cooled to 55 °C, and subsequently mixed
with thrombin (10 NIH units ml−1) for coagulation in a
Petri dish. Serial dilutions of the enzyme solution (1, 2, 3,
4, and 5 U/mL) were prepared in 50 mM sodium phos-
phate buffer, and approximately 15 μl was injected into
sample pools in the fibrin plate and incubated at 37 °C for
18 h. The product of the diameters of two perpendicular
lysis zones was used as the measure of fibrinolytic activity.
The areas of the zones hydrolyzed by the same concentra-
tion of protease were compared.
Total protein concentrations were determined by the
BCA assay kit (Thermo Fisher Scientific, Waltham, MA,
USA) using bovine serum albumin as a standard. Pro-
teins were analyzed on 12 % polyacrylamide gels under
denaturing conditions. BandScan, a software to detect
protein or nucleic acid quantity by gray scanning, was
used for analysis of protein expressed level under differ-
ent conditions [34]. The target protein concentration
was determined by scanning a stained SDS–PAGE with
BandScan software. Gray scanning analysis by BandScan
software showed that the target protein under different
concentrations accounted for the percent of the total
protein. Then the target protein concentration can be
caculated. N-terminal sequencing was performed by
Shanghai Genecore Biotechnologies (Shanghai, China).
Additional files
Additional file 1: Cloning and schematic representation of hμPlg
cloning. Figure (A) represents cloning of hμPlg from plasmid pUC57 to
pPIC9K vector. M – DNA Marker, 1- PCR with gene specific primers using
pUC57 as template, 2- restriction digestion of pPIC9K-hμPlg with XhoI and
SalI, 3- restriction digestion of pPIC9K-hμPlg with NotI and SalI,
4- restriction digestion of pPIC9K-hμPlg with RsrII. Figure (B) represents the
schematic diagrams of pPIC9K-hμPlg.
Additional file 2: Summary of the purification of rhμPlg.
Liu et al. BMC Biotechnology  (2015) 15:50 Page 8 of 8Additional file 3: Nucleotide sequence and corresponding amino
acid sequence of hμPlg. The mature cDNA sequence of rhμPlg encodes
a 261-amion acid peptide.
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